Literature DB >> 11845880

Intermediate results of the anatomic repair for congenitally corrected transposition.

Michel N Ilbawi1, Catherine B Ocampo, Bradley S Allen, Mary Jane Barth, David A Roberson, Pipit Chiemmongkoltip, Rene A Arcilla.   

Abstract

BACKGROUND: Anatomic repair of congenitally corrected transposition of the great arteries has several advantages over the traditional approach but lacks long-term evaluation.
METHODS: The data on 12 patients who had the procedure between January 1989 and June 2000 were retrospectively reviewed. Associated lesions included ventricular septal defect in 12 patients, pulmonary stenosis in 10 patients, and moderate to severe tricuspid valve regurgitation in 4 patients. Mean age at operation was 9+/-3.6 months. All patients had venous switch Mustard procedure. Tunneling of the morphologic left ventricle through the ventricular septal defect to the aorta with insertion of right ventricular to pulmonary artery conduit was performed in 10 patients, and arterial switch operation in 2. Concomitant tricuspid valvuloplasty was done in 2 patients and ventricular septal defect enlargement in 1.
RESULTS: There was one hospital death (9%) in the patient who needed ventricular septal defect enlargement. Complications included atrioventricular block requiring pacemaker insertion in 1 patient (9%) and superior vena caval obstruction in 1 patient (9%). Follow-up is available on all patients 0.5 to 10 years (mean, 7.6+/-3.1 years). All patients are asymptomatic. Exercise test results on the three oldest patients were normal. Bradytachyarrhythmias developed in 4 patients (36%). Right ventricular to pulmonary artery conduit replacement was needed in 5 patients 2.2 to 7.1 years (mean 5.2+/-3.6 years) postoperatively. Mild to moderate tricuspid valve regurgitation persisted in 2 patients. Systemic left ventricular fractional shortening was 36% to 47% (mean, 39%+/-4.6%), and ejection fraction was 49% to 70% (mean, 60.8%+/-7.9%).
CONCLUSIONS: The double switch operation can be performed safely with minimal intermediate and long-term complications.

Entities:  

Mesh:

Year:  2002        PMID: 11845880     DOI: 10.1016/s0003-4975(01)03408-7

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: complex congenital cardiac lesions.

Authors:  Candice K Silversides; Omid Salehian; Erwin Oechslin; Markus Schwerzmann; Isabelle Vonder Muhll; Paul Khairy; Eric Horlick; Mike Landzberg; Folkert Meijboom; Carole Warnes; Judith Therrien
Journal:  Can J Cardiol       Date:  2010-03       Impact factor: 5.223

2.  Cardiorespiratory responses to exercise after anatomic repair of atrioventricular discordance with abnormal ventriculoarterial connection.

Authors:  Kenji Yasuda; Hideo Ohuchi; Yasuo Ono; Toshikatsu Yagihara; Shigeyuki Echigo
Journal:  Pediatr Cardiol       Date:  2006-12-08       Impact factor: 1.655

3.  Long term follow up after surgery in congenitally corrected transposition of the great arteries with a right ventricle in the systemic circulation.

Authors:  Ad J J C Bogers; Stuart J Head; Peter L de Jong; Maarten Witsenburg; Arie Pieter Kappetein
Journal:  J Cardiothorac Surg       Date:  2010-09-28       Impact factor: 1.637

4.  Double switch operation for congenitally corrected transposition of the great arteries after two-staged pulmonary artery banding.

Authors:  Yoshimasa Uno; Kiyozo Morita; Yoshihiro Ko; Katsushi Kinouchi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2006-01

5.  Congenitally Corrected Transposition of the Great Arteries: Current Treatment Options.

Authors:  Karrie Dyer; Thomas P. Graham
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-10

6.  Prenatal diagnosis, associated findings and postnatal outcome in fetuses with congenitally corrected transposition of the great arteries.

Authors:  Andrea Krummholz; I Gottschalk; A Geipel; U Herberg; C Berg; U Gembruch; A Hellmund
Journal:  Arch Gynecol Obstet       Date:  2020-11-20       Impact factor: 2.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.